Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
N/A
18 Years
75 Years
18 Years
75 Years
Open (Enrolling)
Both
Breast Cancer, Bevacizumab, Neoadjuvant Chemotherapy, Molecular Targeted Therapy
Both
Breast Cancer, Bevacizumab, Neoadjuvant Chemotherapy, Molecular Targeted Therapy
Trial Information
Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy
Inclusion Criteria:
- HER2-negative breast cancer patients
- Without surgery
- Plans to neoadjuvant chemotherapy
Exclusion Criteria:
- HER2-positive breast cancer patients
- Post-operative patients
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
Objective Response Rate
Outcome Description:
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.
Outcome Time Frame:
From enrollment to disease progression
Safety Issue:
No
Authority:
China: Food and Drug Administration
Study ID:
QTDS-01
NCT ID:
NCT01652560
Start Date:
June 2012
Completion Date:
September 2014
Related Keywords:
- Breast Cancer
- Bevacizumab
- Neoadjuvant Chemotherapy
- Molecular Targeted Therapy
- bevacizumab
- neoadjuvant chemotherapy
- HER2-negative breast cancer
- Breast Neoplasms
Name | Location |
|---|
